Tramadol intravenous - Revogenex/Avenue Therapeutics

Drug Profile

Tramadol intravenous - Revogenex/Avenue Therapeutics

Alternative Names: RVX 109; Tramadol hydrochloride - Revogenex/Avenue Therapeutics

Latest Information Update: 05 Jan 2017

Price : $50

At a glance

  • Originator Revogenex
  • Developer Avenue Therapeutics
  • Class Antidepressants; Cyclohexanols; Dimethylamines; Erectile dysfunction therapies; Opioid analgesics; Phenyl ethers; Small molecules
  • Mechanism of Action Opioid mu receptor agonists; Serotonin uptake inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase II Postoperative pain

Most Recent Events

  • 16 Mar 2017 Avenue plans three phase III clinical trials (In an orthopaedic model, In a soft tissue model, An open-label safety study) for Postoperative pain in USA
  • 03 Jan 2017 Avenue Therapeutics receives patent allowance for two patent applications for Tramadol intravenous in the US
  • 03 Jan 2017 Avenue Therapeutics has patent protection for Tramadol intravenous in the US
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top